© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Veterinary medicine often pushes pharmaceutical research toward new frontiers, and tildipirosin stands as a case in point. Its development traces back to the ongoing pursuit of better treatments for livestock respiratory diseases, which became more pronounced in the late 20th century as the agricultural industry worked hard to reduce economic losses from outbreaks. Early macrolides had their strengths, but increasing resistance drove researchers to adapt molecular structures. Tildipirosin emerged through continuous exploration of derivatives from tylosin, a well-known macrolide antibiotic. Scientists zeroed in on the distinctive 16-membered ring, which gave tildipirosin its unique power against common pathogens in cattle and swine. As veterinarians watched familiar compounds lose their effectiveness, the pressure grew to bring new, reliable options like tildipirosin to market.
Tildipirosin jumped into veterinary practice as an injectable macrolide antibiotic, targeting respiratory diseases in livestock. Marketed under brand names such as Zuprevo, it quickly gained ground by outperforming predecessors in treating conditions like bovine respiratory disease (BRD) and swine respiratory disease (SRD). Farmers look for drugs that act quickly, require fewer doses, and reduce stress in herds, and tildipirosin offers all those attributes. Most formulations come in ready-to-use solutions, designed for subcutaneous administration, cutting down on handling and risk of injection-site irritation. Cost often comes up in conversations on the farm, but the savings from healthier, faster-recovering animals make a compelling case for investment.
Tildipirosin’s solid physicochemical foundation underpins its practical value. It has a molecular formula of C41H71N3O8S, weighing in at 766.08 g/mol. At room temperature, it appears as a pale, almost translucent powder, easily integrating into specialized solvent mixtures that maximize shelf life and stability. The macrolide ring, key to its performance, resists acidic breakdown and holds firm in the presence of enzymes that would thwart other antibiotics. With limited solubility in water but excellent compatibility with organic solvents, manufacturers carefully select carrier systems. Slightly hygroscopic, it demands airtight packaging, and its melting point—around 120–130°C—reflects its robust structural design. The molecule holds up well under typical storage and transportation conditions, essential for distribution in regions with few luxuries for climate control.
Agricultural professionals count on tildipirosin labels for more than just dosing instructions. They spell out compositions, such as 180 mg of active substance per milliliter, preservative content, and recommended administration routes, mainly subcutaneous injection. Labels also indicate withholding periods for meat, safeguarding consumers and export markets from residue concerns. I’ve found veterinarians in the field sticking close to label instructions, as off-label use comes with traceability and food safety risks. Product packaging carries not only the CAS number (328898-40-4) but also batch information, expiry dates, manufacturing sites, and ISO- or GMP-related assurance. It’s not unusual to see QR codes for instant traceability and updated technical sheets, reflecting shifting global regulatory landscapes.
Manufacturing tildipirosin starts with semi-synthetic modification of tylosin. Scientists employ targeted fermentation processes that produce the tylosin A core, then proceed with chemical modifications—introducing the 3,4,6-trideoxy-3-pyridyl sugar moiety. The synthetic step involves regioselective acylation at the 20th position of the lactone ring, which boosts antimicrobial potency. Process engineers keep a close eye on purification, using solvent extraction, crystallization, and filtration to isolate a high-purity product. The final stage includes blending the active ingredient with excipients—the stabilizers and buffers—before sterilizing and sealing into vials. I’ve heard process chemists comment on the challenge of balancing yield with purity, especially given the vigilance of regulators ensuring zero-risk of cross-contamination or incomplete synthesis.
In the lab, modifications of tildipirosin’s chemical structure offer paths for future improvements. The 16-membered macrolide backbone allows for selective substitutions—adding or swapping out groups to increase spectrum or extend activity duration. Chemical reactions typically involve regioselective oxidation, esterification, or glycosylation, which change solubility or bioavailability. Research circles have tinkered with these alterations, but the regulatory path to approval runs long and expensive. The most successful reactions so far maintain the macrolide core while tweaking side chains to ward off resistant bacterial strains. Transparency in chemistry means regulators expect detailed reaction documentation, trace impurity analysis, and proof that modifications don’t generate new toxic byproducts.
Tildipirosin appears in marketing sheets and scientific papers under a range of synonyms. Besides its designated INN, it comes up as Zuprevo (by MSD Animal Health/Merck) and sometimes as Tildimycin in research circles. Technical catalogues list it by its CAS number and molecular descriptors, sometimes referring to it as a 20-dihydro-20-pyridyl-tylosin derivative. Trade names may differ across countries, but the core ingredient remains the same. On pharmaceutical industry forums, people occasionally debate pronunciation or branding, but efficacy draws more interest than naming conventions.
Handling tildipirosin demands attention to detail. In manufacturing, I’ve seen standard operating procedures that follow stringent ISO and GMP guidelines—personnel wear specialized gear to prevent exposure and cross-contamination, and all mixing rooms are tightly controlled for cleanliness and airflow. Labels outline hazard symbols, first-aid steps for accidental contact, and safe disposal protocols. Environmental protection agencies require wastewater treatment, ensuring byproducts don’t slip into water systems. Use in the field also calls for safety, with ultra-fine needles used to avoid accidental self-injection and clear signage in animal treatment areas to keep non-involved staff out. Continuous training sessions at production plants stress the need for up-to-date safety data sheets, emergency eye wash stations, and pre-job risk assessments.
Tildipirosin earns its keep in commercial animal agriculture, especially intensive beef, dairy, and pork operations. The main targets are Mycoplasma bovis, Mannheimia haemolytica, and Pasteurella multocida—all key culprits behind respiratory outbreaks. Veterinarians sometimes use it for metaphylactic treatment—treating entire pens at the first sign of an outbreak to suppress spread and avoid steep losses. Ranchers appreciate its rapid tissue distribution, reaching lungs within hours and maintaining effective concentrations. In my own dealings with cattle producers, I witness close monitoring post-injection, watching for fever drops and recovery spurts. Although strictly reserved for animal use, tildipirosin’s reputation rides on clear boundaries set by regulatory authorities aiming to minimize risks of antibiotic residues entering the human food chain.
Research doesn’t stop at market launch. University labs and pharmaceutical firms keep pushing to test tildipirosin’s effectiveness against emerging bacterial strains. Clinical trial data inform new protocols, with scientists measuring pharmacokinetics—how long the drug lingers, peak concentrations in different tissues, and differences between species. Field studies track resistance emerging on commercial farms, and every year sees presentations on tildipirosin at international veterinary congresses. Some research works on finding ways to use lower dosages, improving formulations for even less injection pain or faster withdrawal. A few projects tackle the microbiome’s response to macrolide antibiotics, watching for beneficial bacteria get caught in the crossfire. I’ve met with academic researchers who analyze blood and tissue samples from treated animals, mapping out subtle shifts in bacterial populations.
Tildipirosin clears toxicological hurdles to earn approval, but research continues due to growing public concern. Acute and chronic studies on lab animals, including rats and dogs, have helped define safe dose ranges and identify mild, non-life-threatening reactions like temporary injection-site swelling or mild gastrointestinal upset. Producers adhere strictly to label withdrawal periods, which stem from carefully calculated residue studies that reassure food safety. Some more recent studies track environmental impact, watching for antibiotic traces in manure and subsequent soil leaching. Regulatory bodies keep updating risk assessments, factoring in data from both the field and laboratory, making manufacturers invest in long-term ecological and toxicological tracking. During panel discussions, I often hear veterinarians express relief at the relatively low risk of serious residues, but no one underestimates the burden of ongoing vigilance.
Innovation in livestock health faces constant pressure from regulators, consumers, and disease dynamics. Future work on tildipirosin seems destined to focus on smarter dosing schedules, even more rapid-acting formulations, and minimizing resistance buildup. There’s momentum behind point-of-care diagnostics that could help tailor antibiotic use, avoiding blanket metaphylaxis and safeguarding this class of antibiotics for the long term. Biotech companies tap into machine learning to detect early respiratory outbreaks, integrating tildipirosin into data-driven protocols. Producers look for ways to shrink environmental impact, such as optimizing manure management to degrade antibiotic residues safely. Colleges and R&D organizations keep searching for chemical tweaks or delivery alternatives—maybe oral forms or slow-release injectables—without crossing regulatory red lines. Based on my talks with veterinarians, the practical future of tildipirosin depends as much on stewardship and surveillance as on chemical innovation.
Tildipirosin comes up often in conversations about livestock health, especially on farms where respiratory illnesses in cattle cost time and money. For farmers who depend on healthy animals, every tool in the medicine cabinet can mean the difference between a good season and a tough one. Tildipirosin stands out because it steps in to fight respiratory infections that hit cattle herds hard. These infections can spread fast, wiping out any gains ranchers invest months building up.
Bovine Respiratory Disease (BRD) goes beyond the sniffles. It’s a complex group of lung infections that can cost a rancher thousands of dollars in lost weight gain, veterinary bills, and, worst of all, lost animals. BRD doesn’t just stress out a sick cow—her companions and herds that move with her can all get dragged into a downward spiral. Tildipirosin, a macrolide antibiotic, targets the bacteria behind these infections, including Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. The way this drug works, it builds up in lung tissue and stays there for weeks. That gives it staying power, letting it keep working long after the shot goes in.
My uncle raises several hundred head of cattle near a patch of prairie in the Midwest. I remember the worry in his voice during BRD outbreaks—a shuffle of calls to vets, checking on mothers worried about their calves, uneasy glances at a weakening animal. He once said nothing hurts more than watching an animal fight for breath, then seeing more in the herd start coughing. When tildipirosin became widely available, he saw fewer outbreaks spiral out of control. The farm’s vet could make a single visit and deliver the dose underneath the animal’s skin, often catching disease before it spread.
Doctors and farmers know antibiotics are not magic bullets. Bacteria can adapt quickly. That keeps everyone on their toes about using tildipirosin carefully—treat only when there’s clear evidence of infection. This practice builds trust with livestock buyers who care about how animals are raised. Responsible use matters. The FDA, veterinarians, and livestock producers all agree good antibiotic habits mean sticking to recommended dosages, withdrawal periods, and double-checking diagnoses before pulling out a syringe. Consumers have grown more aware of how antibiotics travel from the barn to their plate.
Keeping cattle robust means protecting a way of life for families who depend on them, and supporting local economies that ride on ranch work. Tildipirosin’s ability to stall BRD means herds can thrive even during the harsh weeks when weather and stress leave animals vulnerable. A healthy animal leads to milk for the dairy, beef for the dinner table, and work for the vet, the feed store, and everyone in between.
Treating an infection starts with a watchful eye, a careful hand, and a medicine like tildipirosin that comes with proven science, trust between ranchers and vets, and a clear track record in practice. This mix keeps animals healthier and keeps rural communities moving forward.
Tildipirosin plays a critical role in veterinary medicine, especially for cattle and swine with respiratory challenges. Experience in livestock management teaches that antibiotics aren’t just about picking up any dose off a chart—weight, condition, and the specific animal species all change the calculation. With tildipirosin, the dose for cattle comes down to 4 mg per kilogram of body weight. In plain numbers, a 100-kg calf receives 4 mL of the injectable solution if the standard is 100 mg/mL. For swine, it shifts to a dosage of 4 mg/kg as well, but the practicalities of how the medication is delivered make a difference.
Vets learn quickly that anything less or more than the target dose can throw off recovery. Underdosing leaves pathogens behind, letting illness linger and resistance build. Overdoing it stresses organs and sometimes triggers side effects. The same shot never fits all. That’s why hands-on knowledge from producers, coupled with regular scales, help get it right. A guess can sabotage not just today’s run, but the immunity down the road.
Injectable antibiotics bring a different set of steps compared to drenching or feed additives. Tildipirosin goes deep into the muscle—usually the neck muscle for cattle and into the neck or behind the ear for pigs. Anything else and you risk damaging valuable meat or stressing the animal more than needed. Experience out on the lot shows that calm handling, sharp needles, and quick but steady delivery can mean the difference between a cooperative animal and an injury to both stock and handler.
Each injection site gets a limit; cattle ought not to receive more than 10 mL per spot, swine just 2 mL. Large animals? Divide the dose across two or more locations if needed. These limits come from real concern—stretching muscle tissue or risking abscess formation not only ruins meat, but brings more suffering and slows up recovery.
Withholding periods get overlooked, but food safety depends on it. For cattle, meat cannot enter the food chain for 21 days after treatment. Pigs require at least a 9-day window. Milk from treated animals must be discarded; residues in milk aren't negotiable. Many producers have faced warnings or penalties when this gets shrugged off. Regulatory checks aren’t rare—they keep the market safe for everyone.
Resistance in livestock bacteria sticks in the minds of most farmers and veterinarians who’ve seen once-reliable antibiotics fail. Choosing tildipirosin should come only after a proper diagnosis. A culture and sensitivity test costs extra time up front, but it spares everyone hassle later by narrowing down the drug to match the bug. This step alone can hold back the tide of multi-drug-resistant pathogens on the farm.
Regular check-ins with a trusted veterinarian have bridged the gap between book knowledge and what’s happening in the barn. From experience, following professional guidelines tightly means healthier herds and a better shot at keeping antibiotics useful for the long haul. Straying off-label wastes time and puts markets at risk; nobody benefits from shortcuts involving powerful medications. In the end, correct dosing, careful application, and strict observance of regulations keep both animals and food producers moving forward safely.
Tildipirosin comes up often these days in livestock health circles. The antibiotic belongs to the macrolide class and has turned into a household term for anyone who raises cattle or swine. The world of animal medicine keeps growing, and with that growth, the demand for smart, targeted medication surges as well. Tildipirosin shows up as an answer for some tough problems in the barn and feedlot.
Cattle top the list. Respiratory infections can sweep through a herd in no time, leaving ranchers stressed and animals struggling. Tildipirosin gets used to fight against bovine respiratory disease (BRD). This illness can knock down even sturdy animals. Pathogens like Mannheimia haemolytica lurk in dusty pens and cold snaps, so ranchers want fast action. One dose under the skin gives long-lasting support—many folks see improvement without the hassle of daily injections.
Pigs also benefit, especially when swine respiratory disease runs through a barn. Herds pulling through outbreaks caused by Actinobacillus pleuropneumoniae or Pasteurella multocida have seen solid results. In practice, producers notice fewer coughing fits and better growth rates. Piglets just weaned and older finishers both end up breathing easier after timely intervention.
Livestock get sick, no two ways about it. That sickness costs time, money, and animal welfare. Science has pushed the development of species-specific drugs, and tildipirosin takes its place among them. Using targeted antibiotics reduces the urge to blanket herds or pens with broad drugs that don’t fit. That protects animal health and helps slow down the march of drug resistance.
Veterinarians and producers look for medications that solve problems without adding new ones. Tildipirosin, when used as recommended, targets the bugs causing the greatest headaches in cattle and swine. Using it exactly as labeled matters, whether that means sticking to prescribed dosage or following withdrawal times before animals head to market. Residues in meat lead to consumer distrust, and nobody wants that.
Nobody should reach for tildipirosin unless real need exists. Goats, sheep, poultry, horses, and pets do not fall under its target list. Some people might feel tempted to use livestock products on any animal they raise, but each species has its quirks. Off-label use without guidance risks health problems, wasted efforts, and long-term harm to ecosystems and business reputations.
The Food and Drug Administration (FDA) and equivalent agencies in other countries check every claim drug developers make. Safety tests, tissue sampling, and farm trials have shown tildipirosin works best for cattle and swine. The science says so, not just a label on a bottle.
Farmers and vets both carry heavy responsibilities. Nobody wants resistance piling up or treatments losing their edge. Good record-keeping and close monitoring of animal health trends go a long way. Keeping watch for side effects and staying in touch with veterinarians ensure that each antibiotic course offers the best return. Calling in a vet for a diagnosis (not just to grab a prescription) helps prevent overuse—and that pays off down the line, both for herds and families counting on agriculture.
Raising cattle and pigs comes with its own set of constant challenges. Infectious respiratory diseases hit herds hard, and anyone who has watched a promising group of calves spiral into coughing, fever, and off-feed days knows the heartache well. That's where new antibiotics like tildipirosin get attention. Vets turn to this macrolide under trade names like Zuprevo to hit fast and hard against bovine respiratory disease (BRD) and swine respiratory infections. The hope is always quick recovery and minimum stress for animals. But every tool—especially antibiotics—comes with its trade-offs.
Tildipirosin mainly targets the respiratory bacteria you're fighting—Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni among them. Most animals handle it without much fuss, but occasional side effects do show up. I've seen calves that get a little sore or swollen at the injection site, usually in the first day after administration. Sometimes, they just look off—a little quieter, with mild fever or less appetite for a day or two.
Larger-scale reports show swelling at the injection site to be the most common problem, with percentages varying but rarely climbing above 10% of treated animals. In my own field experience, most cases resolve in a few days without lasting impact. Some animals feel a short-lived drop in feed intake. Severe reactions stay rare, but it's always possible to see allergic responses—hives, breathing trouble, or collapse—which calls for immediate medical attention. These are outliers, but they are nothing producers ignore.
Specific data in swine reflect similar trends: injection site swelling and temporary behavioral changes top the list, with serious complications being very unusual. Poor technique, such as contaminated needles, raises the risk for abscesses with any injectable, so hygiene can't be stressed enough.
Tildipirosin isn’t for every animal or every farm. There’s a clear warning against using it in animals with known sensitivity to macrolide antibiotics. If a previous treatment with drugs like tylosin or tilmicosin caused a reaction—skip tildipirosin. Using it in species not labeled for its use, like goats or horses, pushes into risky territory. Horses, in particular, can react very badly to this whole class of medication.
Drug residues matter for food safety. Strict withdrawal times—at least 21 days for beef cattle sent to slaughter, and specific windows for swine—must be followed to keep meat supply safe for consumers. Extra-label use makes residue risks harder to control and can threaten both herd health and your marketing channels.
Mistakes often come from rushing. Double-check dosages, use proper injection techniques, and separate sick animals to avoid stress and cross-infection. Keeping detailed treatment records helps recognize patterns—if a group of animals seems extra sensitive, raise it with your vet right away. Never use antibiotics, including tildipirosin, as a substitute for good nutrition, ventilation, or basic care. Overuse or misuse of these drugs risks resistance and reduces their value for everyone.
Tildipirosin, handled thoughtfully, provides another weapon against tough respiratory diseases, but every decision to use it should balance the benefits and the possible downsides. Keeping animals healthy starts on the ground—with close attention, clean tools, and constant communication between producers and veterinarians.
Tildipirosin steps in as a key antibiotic for respiratory disease in cattle and swine. Unlike many other veterinary drugs, this compound brings a longer action in the animal’s body. The stakes go up when storage and handling go sideways, risking a drop in performance and even animal safety. Having spent years with livestock pharmaceuticals, I’ve seen how simple habits—good or bad—shape both the shelf life and success of vital drugs like this one.
Heat, light, and moisture spell trouble for tildipirosin. A shelf in the back of a sun-soaked barn doesn’t cut it. The medicine calls for a place away from direct sunlight and far from equipment that gives off heat—think away from engines, radiators, or busy halls. A cool, dry storeroom with a steady temperature under 25°C offers the best shot at keeping the product working as advertised. Freezing isn’t a fix either; freezing tildipirosin can cause crystals that make dosing unreliable or even damage the solution.
Companies use amber-colored vials for a reason. These bottles block light that would otherwise break down the drug over time. Keeping caps tight and bottles sealed protects against moisture and accidental spills. I’ve watched more than one batch cost a farm thousands, just because someone left a bottle half-opened for a day or two during peak summer heat. Taking five seconds to close the bottle beats scrambling for a replacement later.
Handling starts before the first injection. A quick look at the expiry date means one less worry about wasted medicine or botched treatments. After drawing up a dose, the needle or syringe shouldn’t dip back into the bottle—this habit passes along bacteria that invite spoilage. Single-use needles solve a lot of headaches, as they stop cross-contamination that can wreck more than one bottle and compromise animal health.
Leftovers after a dose matter as much as a fresh vial. Returning unused liquid to its original bottle adds risk. Tildipirosin isn’t cheap, and the temptation to “save” product is real, but this short-cut often leads to shortfalls in safety. Once out of the original vial, the product quickly opens itself to contamination by stray dust or microbes. In many barns, staff keep a running log of every vial's opening date and who handled it. This works as a failsafe, flagging bottles that have hung around too long or have changed hands too often.
Leftover medicine shouldn’t end up in sinks, manure pits, or trash cans. Pharmaceuticals like tildipirosin can slip into groundwater or harm local wildlife if handled the wrong way. Most rural veterinarians offer take-back programs or point clients to community drop-offs. These programs take the worry out of disposal and help keep working farms in good standing with strict environmental rules. I’ve found partnership with licensed waste handlers to offer peace of mind and a reputation for responsibility in the community.
Tildipirosin rewards whoever stores and handles it well, with fewer returns, healthier animals, and less lost income. I keep a laminated checklist in the supply closet as a steady reminder for staff and guests. Training shouldn’t only happen once, either. Walk new team members through the how and why. Tildipirosin deserves that effort, and every animal treated relies on it.
| Names | |
| Preferred IUPAC name | (2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-14-[(2-pyridylamino)acetyl]oxy-1-oxa-6-azacyclopentadecan-15-one |
| Other names |
Zuprevo Tildipirosina Tildipirosinum |
| Pronunciation | /ˌtɪl.dɪ.pɪˈrō.sɪn/ |
| Identifiers | |
| CAS Number | “328898-40-9” |
| 3D model (JSmol) | `3D Model (JSmol) String` for **Tildipirosin**: ``` CN1CC[C@H]2[C@H]([C@@H](C[C@@H]3[C@@H](C(=O)O2)CN(C3=O)C)OC(=O)[C@@]4(C)O[C@@H](C[C@]4(C)O)C(=O)NC/C=C(\C)C ``` |
| Beilstein Reference | 3581403 |
| ChEBI | CHEBI:77989 |
| ChEMBL | CHEMBL2105752 |
| ChemSpider | 69825906 |
| DrugBank | DB08867 |
| ECHA InfoCard | 03c07ea7-1f7d-47e1-b37c-62b129e62d55 |
| EC Number | 85721-33-1 |
| Gmelin Reference | 14721536 |
| KEGG | D10616 |
| MeSH | D000077526 |
| PubChem CID | 53321245 |
| RTECS number | XP227L5FSD |
| UNII | 15UQM8GH9D |
| UN number | “UN2810” |
| Properties | |
| Chemical formula | C41H71N3O10S |
| Molar mass | 493.64 g/mol |
| Appearance | Light yellow to yellow solution |
| Odor | Odorless |
| Density | Density: 1.31 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 2.79 |
| Acidity (pKa) | 7.75 |
| Basicity (pKb) | 8.83 |
| Magnetic susceptibility (χ) | -26.1e-6 cm³/mol |
| Refractive index (nD) | 1.612 |
| Dipole moment | 2.61 D |
| Thermochemistry | |
| Std enthalpy of formation (ΔfH⦵298) | -388.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -10110 kJ/mol |
| Pharmacology | |
| ATC code | QJ01FA94 |
| Hazards | |
| Main hazards | May cause an allergic skin reaction. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS09 |
| Pictograms | GHS05,GHS07,GHS09 |
| Signal word | Warning |
| Hazard statements | H302, H317, H319, H334, H335 |
| Precautionary statements | Read Safety Data Sheet before use. Wear protective gloves/protective clothing/eye protection/face protection. If skin irritation occurs: Get medical advice/attention. Avoid release to the environment. |
| NFPA 704 (fire diamond) | 1-2-0 |
| Flash point | > 272.7 °C |
| Lethal dose or concentration | LD₅₀ (rat, oral): > 300-2000 mg/kg |
| LD50 (median dose) | > 3,998 mg/kg (rat, oral) |
| REL (Recommended) | 4 mg/kg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Tulathromycin Tilmicosin Tylosin |
